The most precise antibiotic
ever discovered is a virus.
Bacteriophages are viruses that hunt a single strain of bacteria and nothing else. As antibiotics fail and resistance climbs toward a projected 10 million deaths a year by 2050, engineered phage cocktails are emerging as the precision antibacterials of the post-antibiotic era. This is a scientific exploration of what they are, where they belong, and the industry they will become.
The thesis
Antibiotics carpet-bomb. Phages are snipers.
A broad-spectrum antibiotic kills the infection and most of the microbiome with it — collateral damage that drives C. difficile, dysbiosis, and the very resistance it was meant to defeat. A phage cocktail is the opposite: a curated set of viruses, each locked onto one bacterial strain, that replicate only where the target lives and disappear when it is gone.
That specificity is a feature, not a limitation. It is what lets you remove a single disease-driving strain from a healthy community — the founding promise of microbiome medicine — and it is why the field’s most durable lesson is that phages work best alongside antibiotics, not as a like-for-like replacement.
Phage vs. antibiotic
- Spectrum
- One strain
- Hundreds of species
- Microbiome
- Spared
- Collateral loss
- Self-dosing
- Amplifies at the infection
- Fixed pharmacokinetics
- Biofilms
- Penetrates & degrades
- Poor penetration
- Resistance
- Co-evolves; can be re-matched
- Slow, costly pipeline
Why now
The slow-motion emergency phage cocktails are built for.
Resistance is not a future risk — it is a present, measured death toll, projected to compound for decades. These are the numbers, with sources, kept deliberately honest.
Read the full breakdown on The 2050 Crisis →
Explore
Eight ways into the science
The Science
What phages are, why a cocktail beats a single phage, and how lytic viruses became the most precise antibacterial ever conceived.
Read →The 2050 Crisis
Antimicrobial resistance, the $100-trillion problem, and why phage cocktails are positioned to define a new industry — framed honestly.
Read →Microbiome Medicine
Phages as scalpels for the microbiome: removing one pathobiont from a community of thousands without collateral damage.
Read →50 Applications + 20 Frontiers
Fifty evidence-anchored deployment targets from the literature, plus twenty under-explored frontier ideas — including the NICU flagship.
Read →Research Landscape
The institutes, companies, landmark cases, and funders building the field — from the Eliava Institute to Locus, Armata, and BiomX.
Read →Who's Who
The pioneers, clinical leaders, scientists, and founders driving phage therapy — the people and faces behind the field.
Read →Cancer, by a Virus
Oncolytic viruses that lyse tumors and phages that strip the cancer-driving bacteria from inside them — the viral frontier in oncology.
Read →The Investment Thesis
Why this is a platform, not a pill: the AI-driven discovery hook for tech capital and the biosecurity case for big money.
Read →Flagship Grant
A full proposal concept: a precision phage cocktail to prevent necrotizing enterocolitis in the NICU by targeting Klebsiella.
Read →The flagship application
Stopping NEC in the NICU before it starts.
Necrotizing enterocolitis kills up to a third of the premature infants it strikes — and a Klebsiella bloom in the gut measurably precedes it. The flagship concept on this site is a prophylactic phage cocktail that suppresses that bloom before the bowel is lost: precision antibacterials applied to the most fragile patients we have.
The evidence chain
- 01 · Klebsiella actively replicates ~2 days before NEC onset.
- 02 · Virome transfer prevents NEC in preterm piglets.
- 03 · UV-killing the phages removes the protection.
- 04 · A defined anti-Klebsiella cocktail in infants is untested — and fundable.
Questions